Holen Sie sich die Stockscreener-App
25.83
0.27%
0.07
Handel nachbörslich:
25.95
0.12
+0.46%
Schlusskurs vom Vortag:
$25.76
Offen:
$26.21
24-Stunden-Volumen:
1.43M
Relative Volume:
1.39
Marktkapitalisierung:
$2.26B
Einnahmen:
$23.38M
Nettoeinkommen (Verlust:
$-155.22M
KGV:
-11.79
EPS:
-2.19
Netto-Cashflow:
$-134.36M
1W Leistung:
+3.61%
1M Leistung:
+3.32%
6M Leistung:
+37.47%
1J Leistung:
-32.89%
1-Tages-Spanne:
$25.30
$26.95
1-Wochen-Bereich:
$24.04
$26.95
52-Wochen-Spanne:
$13.45
$39.30
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Firmenname
Ideaya Biosciences Inc
Sektor
Branche
Telefon
650-443-6209
Adresse
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Vergleichen Sie IDYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
25.83 | 2.23B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-22 | Eingeleitet | TD Cowen | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-26 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-11-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2024-03-08 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Outperform |
| 2023-05-24 | Eingeleitet | Goldman | Buy |
| 2023-04-24 | Hochstufung | Stifel | Hold → Buy |
| 2023-03-23 | Eingeleitet | Berenberg | Buy |
| 2023-02-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-28 | Eingeleitet | CapitalOne | Overweight |
| 2022-10-27 | Eingeleitet | Citigroup | Buy |
| 2022-08-15 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-10 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-11 | Eingeleitet | Guggenheim | Buy |
| 2020-10-07 | Eingeleitet | Wedbush | Outperform |
| 2020-09-01 | Eingeleitet | Northland Capital | Outperform |
| 2020-07-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-17 | Eingeleitet | Oppenheimer | Outperform |
| 2019-09-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-17 | Eingeleitet | Citigroup | Buy |
| 2019-06-17 | Eingeleitet | JP Morgan | Neutral |
| 2019-06-17 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
Can IDEAYA Biosciences Inc. be recession proofPortfolio Value Summary & Smart Money Movement Tracker - khodrobank.com
Is IDEAYA Biosciences Inc.’s ROIC above industry averageJuly 2025 Recap & AI Based Buy and Sell Signals - khodrobank.com
Ideaya Biosciences gets coverage initiation at Barclays and Citizens - Seeking Alpha
IDEAYA Biosciences Rings the Opening Bell - Nasdaq
Ideaya submits IND for PRMT5 inhibitor - BioWorld MedTech
IDEAYA Biosciences: Barclays initiates coverage at Overweight, PT $40. - AInvest
IDEAYA enrolls first lung cancer patient in targeted therapy trial - Investing.com
IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer - PR Newswire
Trend analysis for IDEAYA Biosciences Inc. this weekWeekly Stock Recap & High Accuracy Trade Alerts - Newser
Regression analysis insights on IDEAYA Biosciences Inc. performanceJuly 2025 Sector Moves & Weekly Chart Analysis and Trade Guides - Newser
IDEAYA Biosciences: A High-Conviction Biotech Play with Precision Oncology Catalysts - AInvest
Transcript : IDEAYA Biosciences, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-03-2025 09 - MarketScreener
Using Python tools to backtest IDEAYA Biosciences Inc. strategiesMarket Growth Report & Reliable Entry Point Trade Alerts - Newser
Real time scanner hits for IDEAYA Biosciences Inc. explainedIndex Update & Technical Pattern Based Buy Signals - Newser
Will IDEAYA Biosciences Inc. continue its uptrendJuly 2025 Patterns & Free Fast Entry Momentum Trade Alerts - Newser
Is IDEAYA Biosciences Inc. stock risky to hold nowInsider Buying & Advanced Technical Analysis Signals - khodrobank.com
Is IDEAYA Biosciences Inc. gaining market shareWeekly Trend Summary & Stepwise Swing Trade Plans - khodrobank.com
How hedge fund analytics apply to IDEAYA Biosciences Inc. stockJuly 2025 Opening Moves & High Conviction Buy Zone Alerts - Newser
How to forecast IDEAYA Biosciences Inc. trends using time seriesJuly 2025 Levels & Weekly High Conviction Ideas - Newser
IDEAYA Biosciences submits IND for new cancer drug IDE892 - Investing.com
What high frequency data says about IDEAYA Biosciences Inc.Portfolio Value Summary & High Accuracy Trade Signal Alerts - Newser
Analyzing IDEAYA Biosciences Inc. with risk reward ratio chartsJuly 2025 Movers & AI Based Buy and Sell Signals - Newser
Risk adjusted return profile for IDEAYA Biosciences Inc. analyzedMarket Trend Report & Growth-Oriented Investment Plans - Newser
IDEAYA Biosciences submits IND for new cancer drug IDE892 By Investing.com - Investing.com UK
Novel PRMT5 Inhibitor Targets 15-20% of Lung Cancer Patients: IDEAYA's IDE892 Advances to Clinical Stage - Stock Titan
How to escape a deep drawdown in IDEAYA Biosciences Inc.July 2025 Closing Moves & Weekly High Return Forecasts - Newser
Is IDEAYA Biosciences Inc. a cyclical or defensive stock2025 Valuation Update & Safe Entry Zone Tips - khodrobank.com
Why IDEAYA Biosciences Inc. stock attracts strong analyst attentionWeekly Profit Summary & Risk Managed Investment Entry Signals - Newser
Backtesting results for IDEAYA Biosciences Inc. trading strategiesTrade Signal Summary & High Win Rate Trade Tips - Newser
Comparing IDEAYA Biosciences Inc. in custom built stock radars2025 Institutional Moves & Short-Term Trading Alerts - Newser
Will IDEAYA Biosciences Inc. stock recover after recent drop2025 Analyst Calls & Reliable Trade Execution Plans - Newser
Best data tools to analyze IDEAYA Biosciences Inc. stockEarnings Overview Summary & Low Volatility Stock Suggestions - Newser
How to monitor IDEAYA Biosciences Inc. with trend dashboardsJuly 2025 Update & Weekly Stock Breakout Alerts - Newser
In Brief: Servier, IDEAYA Partner On Darovasertib For Uveal Melanoma - insights.citeline.com
Volatility clustering patterns for IDEAYA Biosciences Inc.2025 Fundamental Recap & AI Powered Trade Plan Recommendations - Newser
How to recover losses in IDEAYA Biosciences Inc. stockMarket Growth Review & Weekly Watchlist for Hot Stocks - Newser
Will IDEAYA Biosciences Inc. benefit from geopolitical trendsRate Cut & Weekly Consistent Profit Watchlists - khodrobank.com
Servier pays big for ex-US darovasertib rights - The Pharma Letter
How high can IDEAYA Biosciences Inc. stock go2025 Dividend Review & Real-Time Volume Analysis Alerts - Newser
Servier pays $200M upfront to Ideaya; Zymeworks ends work on T cell engager - Endpoints News
Can IDEAYA Biosciences Inc. rally from current levelsStop Loss & Fast Momentum Entry Tips - Newser
Ideaya Biosciences Shares Jump Following $210 Million Licensing Deal with Servier - MSN
The Oncology Institute, Inc. shares fall 1.18% intraday as IDEAYA Biosciences announces positive trial data for darovasertib and crizotinib combination. - AInvest
IDEAYA Biosciences and Servier in-pact to develop eye cancer treatment - Seeking Alpha
Ideaya Biosciences stock surges after $210 million licensing deal with Servier - Investing.com
Precision Biosciences shares fall 1.22% premarket after IDEAYA Biosciences' partnership with Servier. - AInvest
Is this a good reentry point in IDEAYA Biosciences Inc.Inflation Watch & Weekly Top Stock Performers List - Newser
IDEAYA Biosciences' Strategic Licensing of Darovasertib: A Catalyst for Sustainable Growth and Value Creation - AInvest
IDEAYA Biosciences, Inc. Enters into License Agreement with Les Laboratoires Servier - MarketScreener
Analyzing drawdowns of IDEAYA Biosciences Inc. with statistical tools2025 Historical Comparison & Risk Controlled Stock Pick Alerts - Newser
IDEAYA Biosciences Soars 10.63% on Servier Partnership for Uveal Melanoma Treatment - AInvest
Finanzdaten der Ideaya Biosciences Inc-Aktie (IDYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):